IP Library Granted Patent US 11,045,432
Granted Patent B2
US 11,045,432 · App. 15/247,524 · Granted Jun 29, 2021

Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof

Inventors: John Scott Karolchyk (Lake Hopatcong, NJ); Mark L. Baum (San Diego, CA)
Assignee: Harrow IP, LLC
A61K31/137A61K9/0019A61K9/0048A61K9/0051A61K9/19A61K31/19A61K31/4409A61K45/06A61K47/02A61K47/16A61K47/183B65D25/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,045,432
App. No.
15/247,524
Granted
Jun 29, 2021
Kind
B2
Abstract

Pharmaceutical compositions for intraocular injection are described, the compositions comprise therapeutically effective quantity of lyophilized preservative-free and sulfite-free epinephrine or adrenaline and a metal chelator. Methods for fabricating the compositions and using them for intraocular injections are also described.

Claims (16)

1. A method for preparing an aqueous ophthalmic pharmaceutical composition, the method consisting of combining:

(1) a therapeutically effective quantity of at least one compound selected from the group consisting of epinephrine, phenylephrine, EPI-Shugarcaine and tropicamide;

(2) at least one metal chelator, wherein the metal chelator is ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof;

(3) optionally, at least one anesthetic;

(4) optionally, at least one tonicity adjusting agent comprising sodium chloride;

(5) optionally, hydrochloric acid and/or sodium hydroxide;

(6) optionally, at least one non-steroid anti-inflammatory drug; and

(7) a quantity of sterile water,

wherein the composition is free of sulfites, is free of preservatives and has a pH above 6.0 and below 8.0;

thereby preparing the aqueous ophthalmic pharmaceutical composition.

2. The method of claim 1 , wherein epinephrine is in the form of epinephrine hydrochloride.

3. The method of claim 1 , wherein the pharmaceutically acceptable salt of ethylenediaminetetraacetic acid is disodium edetate.

4. The method of claim 1 , wherein the at least one anesthetic is selected from the group consisting of lidocaine, proparacaine, procaine, tetracaine and combinations thereof.

5. The method of claim 1 , wherein the at least one non-steroid anti-inflammatory drug is selected from the group consisting of ketorolac, ketoprofen, flurbiprofen, bromfenac, diclofenac and combinations thereof.

6. The method of claim 1 , wherein the therapeutically effective quantity of at least one compound is selected from the group consisting of epinephrine, EPI-Shugarcaine and tropicamide.

7. The method of claim 1 , wherein the aqueous composition consists of tropicamide, phenylephrine HCl, at least one metal chelator wherein the metal chelator is ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof, lidocaine HCl, at least one tonicity adjusting agent wherein the tonicity adjusting agent is sodium chloride, hydrochloric acid and/or sodium hydroxide, and sodium diclofenac in sterile water.

Assignments (10)
SECURITY INTEREST Recorded Sep 26, 2025
From: HARROW, INC.; HARROW IP, LLC
To: FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 072384/0781 →
RELEASE OF SECURITY INTEREST Recorded Sep 18, 2025
From: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
To: HARROW IP, LLC
Reel/Frame 072299/0911 →
PATENT SECURITY AGREEMENT Recorded Mar 30, 2023
From: HARROW IP, LLC
To: OAKTREE FUND ADMINISTRATION, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 063205/0708 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY AT REEL/FRAME NO. 62105/0556 Recorded Mar 30, 2023
From: B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT
To: HARROW HEALTH, INC.; HARROW EYE, LLC; HARROW IP, LLC; IMPRIMISRX, LLC; IMPRIMIS NJOF, LLC; IMPRIMISRX NJ, LLC; VISIONOLOGY EQUITY, LLC; VISIONOLOGY, INC.; VISIONOLOGY MSO, INC.
Reel/Frame 063205/0889 →
SECURITY INTEREST Recorded Dec 15, 2022
From: HARROW HEALTH, INC.; HARROW EYE, LLC; HARROW IP, LLC; IMPRIMISRX, LLC; IMPRIMIS NJOF, LLC; IMPRIMISRX NJ, LLC; VISIONOLOGY EQUITY, LLC; VISIONOLOGY, INC.; VISIONOLOGY MSO, INC.
To: B. RILEY COMMERCIAL CAPITAL, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 062105/0556 →
RELEASE OF SECURITY INTEREST Recorded May 7, 2021
From: SWK FUNDING LLC
To: HARROW IP, LLC
Reel/Frame 056174/0332 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Nov 21, 2019
From: HARROW IP, LLC
To: SWK FUNDING LLC, AS COLLATERAL AGENT
Reel/Frame 051079/0453 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2019
From: IMPRIMIS PHARMACEUTICALS, INC.
To: HARROW IP, LLC
Reel/Frame 050985/0969 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jul 19, 2017
From: IMPRIMIS PHARMACEUTICALS, INC.
To: SWK FUNDING LLC, AS COLLATERAL AGENT
Reel/Frame 043258/0581 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2016
From: KAROLCHYK, JOHN SCOTT; BAUM, MARK L.
To: IMPRIMIS PHARMACEUTICALS, INC.
Reel/Frame 039995/0588 →
Continuity (5)
Continuation In Part 14506120 · Oct 3, 2014
Provisional Application 61947778 · Mar 4, 2014
Provisional Application 61892872 · Oct 18, 2013
Provisional Application 61886269 · Oct 3, 2013
Related Publication 20170049721A1 · Feb 23, 2017